CJC-1295 + DAC 10 mg

£44.99

+ Free Shipping
SKU: x-546 Category:

Buy CJC-1295 + DAC 10 mg – Research Peptide for Laboratory Studies

CJC-1295 with Drug Affinity Complex (DAC) is a long-acting analogue of growth hormone-releasing hormone (GHRH) that has attracted scientific interest because of its effects on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) signalling. The 10 mg presentation is intended for qualified laboratory research involving peptide biology, endocrine signalling, pharmacokinetics, and molecular science.

This material is supplied for research purposes only and should not be represented as an approved medicine, nutritional supplement, or treatment.

What Is CJC-1295 + DAC?

CJC-1295 is a synthetic analogue of GHRH. The DAC component contributes to its prolonged circulation by enabling the peptide to bind to albumin, extending its exposure compared with shorter-acting GHRH analogues. Early human research investigated its pharmacokinetic and pharmacodynamic characteristics in healthy adults.

In a controlled study, administration of CJC-1295 produced dose-dependent increases in GH and IGF-I concentrations, with an estimated half-life of approximately 5.8 to 8.1 days. The study demonstrated sustained hormonal effects following administration, making the compound relevant to research into long-acting GHRH signalling.

Research Applications

The scientific interest surrounding this peptide is closely connected with the GH/IGF-1 axis. Researchers can investigate how prolonged GHRH receptor stimulation influences endocrine signalling and how changes in GH secretion relate to downstream IGF-I responses.

Potential laboratory research areas include:

  • Growth hormone signalling research
  • GHRH receptor studies
  • IGF-I pathway investigations
  • Peptide pharmacokinetics
  • Pharmacodynamic research
  • Endocrine biology
  • Molecular signalling studies
  • Analytical peptide research
  • Structure-function investigations

These areas describe scientific research applications rather than established medical uses. Findings from controlled studies should not automatically be interpreted as evidence of clinical effectiveness for particular conditions.

CJC-1295 + DAC 10 mg Product Format

The 10 mg format provides a research-scale quantity for laboratories conducting controlled peptide investigations. Researchers can evaluate the material according to their established experimental protocols and analytical requirements.

When selecting research peptides, laboratories should consider product identity, purity, batch information, storage requirements, packaging integrity, and available analytical documentation. Certificate-of-analysis information and appropriate testing can help researchers assess whether a particular batch is suitable for their planned work.

Researchers should follow the supplier’s storage recommendations and their institution’s laboratory safety procedures. Appropriate protective equipment and controlled handling practices should be used when working with experimental peptide materials.

Why Study Long-Acting GHRH Analogues?

Natural GHRH has a relatively short duration of action, which has encouraged researchers to investigate modified analogues designed to produce more sustained exposure. CJC-1295 was developed as a long-acting analogue, and preclinical work identified its interaction with albumin as an important factor in extending its circulation time.

Human research subsequently examined whether this extended exposure could produce sustained changes in GH and IGF-I. One controlled study reported increased GH concentrations for six days or more and increased IGF-I concentrations for approximately nine to eleven days following administration.

Additional research found that GH secretion remained pulsatile following administration, while mean and trough GH concentrations increased. These observations provide useful information for researchers studying the relationship between GHRH stimulation and endocrine signalling.

Quality Considerations for UK Researchers

For UK laboratories, research material should be sourced with clear specifications and responsible documentation. Product pages should distinguish laboratory research information from medical claims and should clearly identify intended use.

Researchers should verify that their proposed activities comply with applicable UK requirements and institutional policies. Regulatory status is particularly important when dealing with compounds that do not have a UK marketing authorisation. The MHRA states that unlicensed medicines have not received UK marketing authorisation and may not have been assessed by the regulator.

The MHRA also states that medicines without the appropriate licence cannot be advertised to the public as licensed medicines. Businesses should therefore ensure that product descriptions and promotional materials accurately reflect the regulatory status of the material being offered. Research Documentation and Handling

Reliable research workflows benefit from careful batch tracking. Laboratories should record product identifiers, analytical documentation, storage conditions, preparation details, and experimental observations where appropriate.

Researchers should also recognise that published findings may involve specific formulations, administration methods, doses, and experimental populations that do not necessarily correspond to commercially available research materials. Independent verification is therefore important when interpreting scientific literature.

Order for Laboratory Research

For laboratories investigating GHRH signalling, peptide pharmacology, endocrine pathways, and GH/IGF-I biology, the 10 mg format provides a defined quantity for research applications. Researchers should review product documentation before beginning experimental work and establish suitable controls for their specific study design.

The scientific literature provides a foundation for understanding the compound’s pharmacological characteristics, while ongoing research continues to examine the broader implications of long-acting GHRH analogues. Current reviews also emphasise uncertainty surrounding unregulated peptide products and the difference between experimental findings and established clinical applications.

Important Research Disclaimer

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary consumption, self-administration, diagnosis, prevention, or treatment of any disease or medical condition. Research findings should not be interpreted as evidence that this material is an approved therapeutic product.

Researchers should conduct all work in appropriately equipped facilities and comply with relevant institutional, safety, regulatory, and ethical requirements. The information provided on this page is intended to support scientific research and should not be considered medical advice.

Shopping Cart